Anti-VEGF antibody in experimental hepatoblastoma: Suppression of tumor growth and altered angiogenesis

Journal of Pediatric Surgery

Volumn 38, Issue 3, 2003, Pages 308-314

  McCrudden, Kimberly W ^a   Hopkins, Benjamin ^a   Frischer, Jason ^a   Novikov, Anna ^a   Huang, Jianzhong ^a   Kadenhe, Angela ^a   New, Tamara ^a   Yokoi, Akiko ^a   Yamashiro, Darrell J ^a   Kandel, Jessica J ^a   Middlesworth, William ^a,b   Grosfeld, J ^c   Gittes, G ^c   Chochat, S ^c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Internal Medicine New York Presbyterian   (United States)

^c NONE

Author keywords

Angiogenesis; Anti VEGF antibody; Hepatoblastoma; Vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; CANCER INHIBITION; CHILDHOOD CANCER; CONFERENCE PAPER; CONTROLLED STUDY; FLUORESCENCE ANGIOGRAPHY; HEPATOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VOLUME; VASCULAR SMOOTH MUSCLE; XENOGRAFT;

EID: 0037370294     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2003.50099     Document Type: Conference Paper

References (23)

1. Raney B: Hepatoblastoma in children: A review. J Pediatr Hematol Oncol 19:418-422, 1997
2. Von Schweinitz D, Hecker H, Schmidt-von-Arndt G, et al: Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer 74:593-599, 1997
3. Ortega JA, Krailo MD, Haas JE, et al: Effective treatment of unresectable or metastatic hepatoblastoma with cisplatin and continuous infusion doxorubicin chemotherapy: A report from the Childrens Cancer Study Group. J Clin Oncol 9:2167-2176, 1991
4. Von Schweinitz D, Hecker H, Harms D, et al: Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma - A report from the German Cooperative Liver Tumor Study HB-89. J Pediatr Surg 30:845-852, 1995
5. Herzog CE, Andrassay RJ, Eftekhari F: Childhood cancers: Hepatoblastoma. Oncologist 5:445-453, 2000
6. McCrudden KW, Yokoi A, Thosani A, et al: Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg 37: 857-861, 2002
7. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
8. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
9. Leung DW, Cachianes G, Kuang WJ, et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
10. Senger DR, Perruzzi CA, Feder J, et al: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632, 1986
11. Brown LF, Berese B, Jackman RW: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in human breast cancer. Hum Pathol 26:86-91, 1995
12. Warren RS, Yuan H, Matli MR, et al: Regulation by vascular endothelial growth factor of human colon cancer in a mouse model of experimental liver metastases. J Clin Invest 95:1789-1797, 1995
13. Boocock CA, Charnock-Jones DS, Sharkley AM: Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. JNCI 87:506-516, 1995
14. Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
15. Melnyk O, Zimmerman M, Jin Kim J, et al: Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model. J Urol 161:960-963, 1998
16. Rowe DH, Huang J, Kayton ML, et al: Suppression of primary tumor growth and metastasis in an experimental model of Wilms tumor. J Pediatr Surg 35:30-33, 2000
17. Rowe DH, Huang J, Li J, et al: Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35:977-981, 2000
18. DeVore R, Herbst RS, Langer CJ, et al: Randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:1896-1902, 2000
19. Bergsland E, Fehrenbacher L, Meropol NJ, et al: A randomized phase II trial of rhumMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc A Soc Clin Oncol 19:939-945, 2000
20. Genentech: National Cancer Institute (NCI) trial studying Genentech's Avastin in advanced kidney cancer reaches pre-specified efficacy endpoint. Genentech (www.gene.com), 2001 http://www.gene. com/gene/news/detail.jsp?detail=4685&pNo= 1&search=1&keyword=avastin+
21. Benjamin LE, Golijanin D, Itin A, et al: Selective ablation of immature blood vessels in established humor tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165, 1999
22. Kim E, Moore J, Huang J, et al: All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg 36:287-290, 2001
23. Petit AM, Rak J, Hung MC, et al: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-30, 1997